Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.
source https://www.sciencedaily.com/releases/2025/01/250125152749.htm
Khelo India Winter Games: Army Men In Ice Hockey Final, Medal Tally Led
By...
-
Hosts Ladakh and Tamil Nadu are joint second in the standings with a day to
go in the first part of KIWG 2025
source
https://sports.ndtv.com/athletics/khe...
6 hours ago
Welcome to the 'The Fact Factory' friends. Its an interesting Hot Spot which brings to you amazing and little known facts from all over the world. So, sit back, take a tour around the world and enjoy the trivia.
No comments:
Post a Comment